TransMedics Group Q1 2023 Earnings Report $71.95 -3.50 (-4.64%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast TransMedics Group EPS ResultsActual EPS-$0.08Consensus EPS -$0.25Beat/MissBeat by +$0.17One Year Ago EPS-$0.38TransMedics Group Revenue ResultsActual Revenue$41.60 millionExpected Revenue$36.05 millionBeat/MissBeat by +$5.55 millionYoY Revenue Growth+161.60%TransMedics Group Announcement DetailsQuarterQ1 2023Date5/1/2023TimeAfter Market ClosesTMDX Upcoming EarningsTransMedics Group will be holding an earnings conference call on Thursday, February 27 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptPress ReleaseTMDX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by TransMedics Group Earnings HeadlinesLowey Dannenberg Notifies TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmFebruary 21 at 5:32 PM | globenewswire.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics GroupFebruary 21 at 4:38 PM | markets.businessinsider.comTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…February 22, 2025 | Porter & Company (Ad)TRANSMEDICS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDXFebruary 21 at 1:30 PM | globenewswire.comTransMedics Group (TMDX) Faces Class-Action Suit Over Alleged Fraud and Safety Lapses- Hagens BermanFebruary 21 at 9:30 AM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit - TMDXFebruary 21 at 5:45 AM | prnewswire.comSee More TransMedics Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TransMedics Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your email. Email Address About TransMedics GroupTransMedics Group (NASDAQ:TMDX), a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.View TransMedics Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
